Southwest Labs LLC

Southwest Labs LLC was paid $41.48M by Medicaid between Jan 2018 and Dec 2024, across 143 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 35% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New Mexico

Rank by total paid#2 of 11

Median peer was paid$1.26M

This provider vs. median33×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	20,700	$2.15M
2019	27,454	$3.05M
2020	34,548	$2.86M
2021	50,963	$3.69M
2022	82,064	$6.30M
2023	101,130	$10.02M
2024incomplete	123,018	$13.41M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	35%	76,789	42,088	$14.68M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	22%	19,858	18,683	$8.93M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	8.9%	67,936	34,853	$3.70M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	5.0%	14,200	12,217	$2.06M
87632		3.6%	6,319	6,062	$1.48M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	3.5%	12,439	6,662	$1.46M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	3.0%	17,905	15,493	$1.24M
87481		2.1%	15,981	15,038	$879K
87653		1.7%	20,855	19,730	$711K
87641		1.7%	20,643	19,508	$704K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.7%	5,637	4,596	$703K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	1.6%	19,663	18,674	$670K

131 more codes

87500		1.3%	16,331	$541K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	11,775	$396K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	11,293	$381K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	12,153	$274K
87581		<1%	7,336	$255K
87529		<1%	7,235	$239K
87486		<1%	6,699	$237K
87541		<1%	6,262	$224K
87496		<1%	6,241	$223K
87498		<1%	6,556	$202K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	3,836	$176K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	2,001	$164K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	4,151	$138K
87563		<1%	3,944	$118K
87511		<1%	3,331	$117K
87640		<1%	2,522	$87K
80050	General health panel	<1%	1,601	$63K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	1,217	$45K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	1,689	$43K
87634		<1%	476	$30K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	394	$29K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	950	$28K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	77	$28K
80061	Lipid panel	<1%	2,238	$24K
84443	Thyroid stimulating hormone (TSH)	<1%	1,249	$19K
87551		<1%	204	$17K
80053	Comprehensive metabolic panel	<1%	1,403	$16K
83036	Hemoglobin; glycosylated (A1C)	<1%	1,639	$14K
84481		<1%	854	$13K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	1,627	$10K
82607		<1%	782	$10K
80074		<1%	222	$9K
84439		<1%	1,216	$8K
87507		<1%	26	$6K
86780		<1%	688	$6K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	364	$5K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	355	$5K
86703		<1%	442	$4K
83013		<1%	64	$4K
86803		<1%	372	$3K
80076		<1%	445	$3K
80048	Basic metabolic panel (calcium, ionized)	<1%	376	$3K
84403		<1%	87	$2K
82728		<1%	126	$2K
84480		<1%	323	$2K
84152		<1%	108	$2K
80069		<1%	201	$1K
83550		<1%	143	$1K
83540		<1%	223	$1K
84436		<1%	205	$1K
86140		<1%	215	$1K
82746		<1%	100	$1K
84702		<1%	129	$1K
84402		<1%	47	$1K
82670		<1%	44	$979.79
87086	Culture, bacterial; quantitative colony count, urine	<1%	144	$967.86
87522	Neg quan hep c or qual rna	<1%	32	$952.22
87340		<1%	113	$895.45
85652		<1%	302	$830.91
84207		<1%	22	$697.98
83001		<1%	42	$625.89
85027		<1%	116	$600.20
87081		<1%	105	$578.17
84446		<1%	40	$577.31
82248		<1%	138	$575.58
84100		<1%	138	$552.75
81003		<1%	405	$543.99
83992		<1%	139	$523.44
86376		<1%	35	$455.00
86609		<1%	41	$429.20
86762		<1%	41	$421.70
87425		<1%	41	$399.97
87329		<1%	41	$389.83
81001		<1%	148	$384.61
86800		<1%	27	$383.67
86431		<1%	81	$382.28
84597		<1%	24	$373.66
84590		<1%	24	$316.19
86850		<1%	39	$272.45
82180		<1%	23	$269.47
86696		<1%	16	$255.69
86592		<1%	56	$241.15
84270		<1%	12	$232.92
86704		<1%	54	$224.46
86708		<1%	56	$219.12
80346		<1%	215	$218.74
80323		<1%	242	$215.27
80348		<1%	199	$200.47
80354		<1%	200	$199.93
86709		<1%	56	$199.07
80361		<1%	214	$194.08
80356		<1%	200	$193.29
80353		<1%	200	$193.25
86695		<1%	16	$174.32
80372		<1%	142	$173.84
80373		<1%	226	$170.29
80359		<1%	200	$169.73
83735		<1%	30	$169.13
80358		<1%	171	$167.17
80365		<1%	199	$163.14
86039		<1%	17	$161.49
80349		<1%	178	$161.23
85045		<1%	36	$160.22
80333		<1%	144	$155.20
86038		<1%	14	$146.40
80344		<1%	86	$136.92
83690		<1%	24	$128.83
80345		<1%	86	$121.54
83525		<1%	13	$119.37
82947		<1%	38	$117.79
80337		<1%	160	$116.76
80363		<1%	83	$108.57
80338		<1%	86	$105.02
86901		<1%	43	$94.15
86900		<1%	43	$94.15
80360		<1%	93	$74.18
82570		<1%	16	$74.08
80357		<1%	143	$73.00
82043		<1%	14	$72.24
80368		<1%	64	$62.22
80355		<1%	123	$54.11
80371		<1%	106	$53.63
80325		<1%	140	$50.82
80367		<1%	27	$20.57
80362		<1%	70	$18.60
80370		<1%	29	$9.04
80321		<1%	18	$6.63
80366		<1%	30	$6.34
80320		<1%	18	$5.04
80324		<1%	87	$2.80
80343		0%	31	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBALDWIN, EVAN (PARTNER / MEDICAL DIRECTOR)